You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

The HER2 View on Breast Cancer

  • Authors: Shanu Modi, MD; Sara M. Tolaney, MD, MPH; Carey K. Anders, MD; Sara A. Hurvitz, MD; Ian E. Krop, MD, PhD; Reshma Mahtani, DO; Mark D. Pegram, MD; Antonio C. Wolff, MD, FACP, FASCO
  • CME / ABIM MOC / CE Released: 11/2/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 11/2/2022
Start Activity


Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists, pathologists, surgeons, nurses, nurse practitioners, physician assistants, and pharmacists.

The goal of this activity is to improve clinicians' understanding of the spectrum of breast cancer treatment and provide strategies that can help translate data updates to improvements in patient care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data on newer therapies for the treatment of all subtypes and stages of breast cancer
  • Have greater competence related to
    • Personalizing treatment for patients with breast cancer
    • Managing treatment-related adverse events (TRAEs) in patients with breast cancer
  • Demonstrate greater confidence in their ability to
    • Provide patient-centered care across all subtypes and stages of breast cancer


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Shanu Modi, MD

    Breast Medical Oncologist​
    Memorial Sloan Kettering Cancer Center​
    Associate Professor of Medicine​
    Weill Cornell Medical College​
    New York City, New York

    Disclosures

    Disclosure: Shanu Modi, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Daiichi Sankyo; Macrogenics
    Served as a speaker or a member of a speakers bureau for: AstraZeneca; Daiichi Sankyo; Genentech; Seattle Genetics
    Received grants for clinical research from: AstraZeneca; Daiichi Sankyo; Genentech; Seattle Genetics

  • Sara M. Tolaney, MD, MPH

    Associate Director
    Susan F. Smith Center for Women's Cancers
    Assistant Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Harvard Medical School
    Boston, Massachusetts

    Disclosures

    Disclosure: Sara M. Tolaney, MD, MPH, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharma; Bristol Myers Squibb; Certara; Chugai Pharma; CytomX; Daiichi Sankyo; Eisai; Eli Lilly; Ellipses Pharma; Genentech/Roche; Infinity Therapeutics; Immunomedics/Gilead; Merck; Mersana Therapeutics; Nanostring; Nektar; Novartis; Odonate; OncoPep; OncoSec; OncXerna; Pfizer; Puma; Sanofi; Seattle Genetics
    Received grants for clinical research from: AstraZeneca; Bristol Myers Squibb; Cyclacel; Eisai; Eli Lilly; Exelixis; Genentech/Roche; Immunomedics/Gilead; Merck; Nanostring; Nektar; Novartis; Odonate; Pfizer; Sanofi; Seattle Genetics

  • Carey K. Anders, MD

    Medical Director, ​
    Duke Cancer Center Brain Tumor Clinic
    Duke Cancer Center Breast Clinic ​
    Duke Health ​
    Durham, North Carolina ​

    Disclosures

    Disclosure: Carey K. Anders, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Athenex; Eisai; Elucida; Genentech; Immunomedics; IPSEN; Novartis; Seattle Genetics
    Received grants for clinical research from: G1-Therapeutics; Lilly; Merck; Nektar; Novartis; Pfizer; Puma; Seattle Genetics; Tesaro; Zion

  • Sara A. Hurvitz, MD

    Medical Oncologist​
    Director​
    Breast Cancer Clinical Research Program​
    Co-Director​
    Santa Monica – UCLA Outpatient Hematology/Oncology
    Practice​
    Assistant Professor of Medicine​
    Division of Hematology/Oncology​
    David Geffen School of Medicine at UCLA​
    Santa Monica, California ​

    Disclosures

    Disclosure: Sara A. Hurvitz, MD, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: Ambrx; Amgen; AstraZeneca; Arvinas; Bayer; Daiichi Sankyo; Dignitana; Genentech/Roche; Gilead; GlaxoSmithKline; Immunomedics; Lilly; Macrogenics; Novartis; Pfizer; OBI Pharma; Phoenix Molecular Designs, Ltd. Pieris; PUMA; Radius; Samumend; Sanofi; Seattle Genetics; Zymeworks
    Owns stock, stock options, or bonds from: NKMax

  • Ian E. Krop, MD, PhD

    Associate Professor of Medicine​
    Harvard Medical School​
    Associate Chief​
    Division of Breast Oncology​
    Dana-Farber Cancer Institute​
    Boston, Massachusetts​

    Disclosures

    Disclosure: Ian E. Krop, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Bristol Myers Squibb; Celltrion; Context Therapeutics; Daiichi Sankyo; Genentech/Roche; Macrogenics; Merck; Novartis; Seattle Genetics; Taiho Oncology
    Received grants for clinical research from: Genentech/Roche; Macrogenics; Pfizer

  • Reshma Mahtani, DO

    Associate Professor of Medicine​
    Co-Leader, Breast Cancer Program​
    Sylvester Cancer Center​
    University of Miami ​
    Miami, Florida​

    Disclosures

    Disclosure: Reshma Mahtani, DO, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Agendia; Amgen; AstraZeneca; Biotheranostics; Daiichi Sankyo; Immunomedics; Lilly; Merck; Novartis; Pfizer; Puma; Sanofi; SeaGen
    Received grants for clinical research from: Genentech

  • Mark D. Pegram, MD

    Susy Yuan-Huey Hung Professor of Oncology​
    Director, Clinical/Translational Research Unit​
    Associate Director for Clinical Research​
    Associate Dean for Clinical Research Quality​
    Stanford University School of Medicine
    Stanford, California

    Disclosures

    Disclosure: Mark D. Pegram, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Daiichi Sankyo; Roche/Genentech; Seattle Genetics

  • Antonio C. Wolff, MD, FACP, FASCO

    Professor of Oncology​
    Director, Breast Cancer Trials​
    Women’s Malignancies Disease Group​
    The Johns Hopkins Kimmel Cancer Center​
    Baltimore, Maryland​

    Disclosures

    Disclosure: Antonio C. Wolff, MD, FACP, FASCO, has disclosed no relevant financial relationships.

Editor

  • Davecia R. Cameron, MS

    Director of Content Development, Medscape, LLC

    Disclosures

    Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 2.0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

The HER2 View on Breast Cancer

Authors: Shanu Modi, MD; Sara M. Tolaney, MD, MPH; Carey K. Anders, MD; Sara A. Hurvitz, MD; Ian E. Krop, MD, PhD; Reshma Mahtani, DO; Mark D. Pegram, MD; Antonio C. Wolff, MD, FACP, FASCOFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 11/2/2021

Valid for credit through: 11/2/2022

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Assessing HER2 in Breast Cancer

Dr Antonio Wolff discusses testing for HER2-positive breast cancer.
Antonio C. Wolff, MD, FACP, FASCO

Treatment of Stage I HER2-Positive Breast Cancer

Dr Sara Tolaney describes the treatment landscape associated with stage I HER2-positive breast cancer.
Sara M. Tolaney, MD, MPH

Approaches to the Treatment of HER2-Postive Early Breast Cancer 

Dr Mark Pegram discusses the selecting treatment for HER2-positive early breast cancer.
Mark D. Pegram, MD

Novel Approaches to Escalate & De-Escalate Therapy for Early-Stage HER2-Positive Breast Cancer 

Dr Sara Hurvitz discusses approaches for escalating and de-escalating therapy in early stage disease.
Sara A. Hurvitz, MD

Selecting and Sequencing Treatment: Metastatic Treatments in Context

Dr Shanu Modi presents data on selecting and sequencing treatment for metastatic HER2-positive breast cancer.
Shanu Modi, MD

Treatment Approaches for HER2-Positive Brain Metastases

Dr Carey Anders presents data on treatment approaches for HER2-positive breast cancer.
Carey K. Anders, MD

Emerging Approaches for HER2-Positive Disease

Dr Ian Krop presents novel and emerging data on HER2-positive targeted therapies.
Ian E. Krop, MD, PhD

Putting the Patient First: Toxicity Management

Dr Reshma Mahtani discusses adverse event management in patients treated for HER2-positive breast cancer.
Reshma Mahtani, DO
 
  • Print